The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly

References

• Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2006;55:10–30.
   Web of Science ®Google Scholar
• Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488–3515.
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer. Lancet. 2011;378:1079–1088.
   PubMed Web of Science ®Google Scholar
• Balducci L. Extermann management of cancer in the older person: a practical approach. The Oncologist. 2000;5:224–237.
   PubMedGoogle Scholar
• Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am. 2000;14:63–77.
   PubMed Web of Science ®Google Scholar
• Corre R, Greillier L, Le Cae ̈R H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non–small-cell lung cancer: the phase iii randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol. 2016;34:1476–1483.
   PubMed Web of Science ®Google Scholar
• Pawelec G Immunosenescence comes of age. Symposium on aging research in immunology: the impact of genomics. EMBO Rep. 2007;8:220–223
   Google Scholar
• Nikolich-Zugich J. Age-associated T-cell clonal expansions (TCE) in vivo – implications for pathogen resistance: cellular immunosenescence – T cells. In: Handbook on Immunosenescence: basic understanding and clinical applications. The Netherlands: Springer; 2009. p. 219–233.
   Google Scholar
• Haynes L, Eaton SM. The effect of age on the cognate function of CD4+ T cell. Immunol Rev. 2005;205:220–228.
   PubMed Web of Science ®Google Scholar
• Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog. 2013;18:573–583.
   PubMedGoogle Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer 
immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Funakoshi T, Muss H, Moschos S. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A meta-analysis of randomized controlled trials. Cancer Immunol Res. 2016 January;1((4)(1Supplement)):A159.
   Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;9,373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;22,373(17):1627–1639.
   Web of Science ®Google Scholar
• CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice (ic) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1) − positive NSCLC. Presented at the Presidential Symposium 2 on Sunday, 9 October, ESMO 2016, Abstract LBA7_PR
   Google Scholar
• Grossi F, Crinò L, Misino A, et al. Efficacy and safety of nivolumab in elderly patients with advanced squamous NSCLC participating in the expanded access programme in Italy. 1079P. Ann of Oncol. 2016;27(suppl 6):vi359–378.
   Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;9,387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   Google Scholar
• Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Presented at the Presidential Symposium 2 on Sunday 9 October, ESMO 2016, Abstract LBA44_PR
   Google Scholar
• Hellmann MD, Gettinger SN, Goldman JW, et al. CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol. 2016;34(suppl):abstr 3001.
   Google Scholar
• Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299–308.
   PubMed Web of Science ®Google Scholar
• Freeman M, Weber J. Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma. J Immunother Cancer. 2015;3(Suppl 2):P133.
   Google Scholar
• Manoussakis MN, Tzioufas AG, Silis MP, et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol. 1987;69:557–565.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Ramalingam SS, et al. Nivolumab (NIVO) safety profile: summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;51:S631.
   Google Scholar
• Singh H, Kim G, Maher VE, et al. FDA subset analysis of safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol. 2016;34(suppl):abstr 10010.
   Google Scholar
• Helisseya C, Vicierb C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol. 2016;7:325–333.
   PubMed Web of Science ®Google Scholar
• European medicines agency: EMEA/H/C/003985 — nivolumab product information 19/06/2015 Opdivo, http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_Product _Information/human/003985/WC500189765.pdf, [ July 2015]
   Google Scholar
• European medicines agency: EMEA/H/C/003820 — pembrolizumab product information 17/07/2015 Keytruda, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990. pdf, [ July 2015]
   Google Scholar
• Opdivo FDA label: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s 012lbl.pdf
   Google Scholar
• Keytruda FDA label: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s 005lbl.pdf
   Google Scholar